



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Tod M. Woolf  
Title: IMPROVED ANTISENSE  
OLIGOMERS  
Appl. No.: 10/624,447  
Filing Date: 07/21/2003  
Examiner: J.J. Zara  
Art Unit: 1635

**CERTIFICATE OF MAILING**  
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on the date below.

DIANE GARCIA  
(Printed Name)  
[Signature]  
(Signature)  
10-21-2003  
(Date of Deposit)

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Applicant submits herewith a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/295,189, filed 04/20/1999. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

**RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy all forms be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date 21 October 2003

By Wesley B. Ames

FOLEY & LARDNER

Customer Number: 30542

Telephone: (858) 847-6714

Facsimile: (858) 792-6773

Wesley B. Ames

Attorney for Applicant

Registration No. 40,893

APPLICANT FACSIMILE OF FORM PTO-1449  
REV 7-80

 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

SERIAL NO.

SRI-004

09/295,189

 LIST OF PUBLICATIONS CITED BY APPLICANT  
(Use several sheets if necessary)

APPLICANT

Tod M. Woolf

FILING DATE

April 20, 1999

GROUP

## U.S. PATENT DOCUMENTS

INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,594,121	1/97	Froehner et al.	536	23.5	
	AB	5,830,653	11/98	Froehler et al.	435	6	
	AC	5,777,153	7/98	Lin et al.	560	158	
	AD	5,955,589	9/99	Cook, et al.	536	23.1	

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

AE	Dean, Nicholas M. and Griffey, Richard H. (1997) "Identification and Characterization of Second-Generation Antisense Oligonucleotides" Antisense & Nucleic Acid Drug Development Vol. 7 pp. 229-233;
AF	Escude, Christophe et al. (1996) "Stable Triple Helices Formed by Oligonucleotide N3' → P5' Phosphoramidates Inhibit Transcription Elongation" Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 4365-4369;
AG	Escude, Christophe et al. (1998) "Rational Design of a Triple Helix-Specific Intercalating Ligand" Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3591-3596;
AH	Flanagan, W. Michael et al. (1999) "A Cytosine Analog That Confers Enhanced Potency To Antisense Oligonucleotides" Proc. Natl. Acad. Sci. USA, Vol. 96, pp. 3513-3518;
AI	Helene, Claude and Thuong, Nguyen T. (1989) "Control of Gene Expression by Oligonucleotides Covalently Linked to Intercalating Agents" Genome, Vol. 31, pp. 413-421;
AJ	Giovannangeli, Carne and Helene, Claude (1997) "Progress In Developments of Triplex-Based Strategies" Antisense & Nucleic Acid Drug Development, Vol. 7, pp. 413-421;
AK	Gutierrez, Arond J. et al. (1997) "Antisense Gene Inhibition by C-5-Substituted Deoxyuridine-Containing Oligodeoxynucleotides" Biochemistry, Vol. 36, pp. 743-748;
AL	Hoke, Glenn D. et al. (1991) "Effects of Phosphorothioate Capping On Antisense Oligonucleotide Stability, Hybridization and Antiviral Efficacy Versus Herpes Simplex Virus Infection" Nucleic Acids Research, Vol. 19, No. 20 pp. 5743-5748;
AM	Jarvis, Thale C. et al. (1996) "Optimizing The Cell Efficacy of Synthetic Ribozymes" The Journal of Biological Chemistry, vol. 271, No. 46, pp. 29107-29112;
AN	Kukreti, Shrikant et al. (1997) "Extension of the Range of DNA Sequences Available For Triple Helix Formation: Stabilization of Mismatched Triplexes By Acridine-Containing Oligonucleotides", Nucleic Acids Research, Vol. 25, No. 21 pp. 4264-4270;
AO	Lacoste, Jerome et al. (1997) "Triple Helix Formation With Purine-Rich Phosphorothioate-Containing Oligonucleotides Covalently Linked To an Acridine Derivative" Nucleic Acids Research, Vol. 25, No. 10 pp. 1991-1998;
AP	Lewis, Jason G. et al. (1996) "A Serum-Resistant Cytofectin For Cellular Delivery of Antisense Oligodeoxynucleotides And Plasmid DNA" Proc. Natl. Acad. Sci. USA, Vol 93, pp. 3176-3181;
AQ	Marchand, Christophe et al. (1996) "Stabilization of Triple Helical DNA by A Benzopyridoquinoxaline Intercalator" Biochemistry, Vol. 35, pp. 5022-5032;

Examiner

Date Considered

\*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449  
REV 7-80

 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

SERIAL NO

SRI-004

09/295,189

 LIST OF PUBLICATIONS CITED BY APPLICANT  
(Use several sheets if necessary)

APPLICANT

Tod M. Woolf

FILING DATE

April 20, 1999

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

BA	Matteucci, Mark D. and Wagner, Richard W. (1996) "In Pursuit of Antisense" Nature, Vol. 384 Supp, pp. 20-23;
BB	McKay, Robert A. et al. (1996) "Enhanced Activity of an Antisense Oligonucleotide Targeting Murine Protein Kinase C- $\alpha$ by the Incorporation of 2'-O-Propyl Modifications" Nucleic Acids Research, Vol. 24, No. 3, pp. 411-417;
BC	Milligan, John F. et al. (1993) "Current Concepts In Antisense Drug Design" Journal of Medicinal Chemistry, vol. 36, No. 14 pp. 1924-1937;
BD	Moulds, Courtney et al. (1995) "Site and Mechanism of Antisense Inhibition By C-5 Propyne Oligonucleotides" biochemistry, Vol. 34, pp. 5044-5053;
BE	Ortigao, Flavio J. et al. (1992) "Antisense Effect of Oligodeoxynucleotides With Inverted Terminal Internucleotideic Linkages: A Minimal Modification Protecting Against Nucleolytic Degradation" Antisense Research And Development, Vol. 2, pp. 129-146;
BF	Stein, C.A. and Cheng, Y.C. (1993) "Antisense Oligonucleotides As Therapeutic Agents - Is the Bullet Really Magical?", Science Vol. 261, pp. 1004-1012;
BG	Wagner, Richard W. et al. (1993) "Antisense Gene Inhibition by Oligonucleotides Containing C-5 Propyne Pyrimidines" Science, Vol. 260, pp. 1510-1513;
BH	Wagner, Richard W. et al. (1996) "Potent and Selective Inhibition of Gene Expression By an Antisense Heptanucleotide" Nature Biotechnology, Vol. 14, pp. 840-844;
BI	Wilson, David. W. et al. (1993) "DNA Triple-Helix Specific Intercalators As Antigene Enhancers: Unfused Aromatic Cations" Biochemistry, Vol. 32, pp. 10614-10621;

Examiner

Date Considered

\*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



09/295189

1635

## NOTICE OF REFERENCES CITED

APPLICANT(S)

TOD M. WOOLF

## U.S. PATENT DOCUMENTS

	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
A	5744555	APRIL 28, 1998	SRIVASTAVA ET AL.	536	26.23	+
B	5801154	SEP. 1, 1998	BARACHINI ET AL.	514	44	
C	5929042	JUL. 27, 1999	TROY ET AL.	514	44	
D	5965720	OCT 12, 1999	GYAZNOV ET AL.	536	23.1	
E	5734040	MAR 31, 1999	WEEKS ET AL.	536	24.5	
F	5594122	JAN 14, 1999	FRIESEN ET AL.	536	24.5	
G	5849902	DEC 15, 1998	ARROW ET AL.	36	24.5	
H						
I						
J						
K						

## FOREIGN PATENT DOCUMENTS

*	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS	PERTINENT SHTS. DWG.	PP. SPEC.
L								
M								
N								
O								
P								
Q								

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)


R	Heidenreich, et AL. 1994. J. OF BIOL. Chem. Vol 269: 2131-2138.
S	Bennett et AL. 1992. MOLECULAR Pharmacology. Vol 41: 1023-1033.
T	Uhlmann et AL. 1990. Chemical Reviews. Vol. 90: 544-579.
U	Crooke, et AL. 1998. Antisense Research & Application. Vol. 1: 50. Springer-Verlag, Berlin.

EXAMINER

JANE ZARA

DATE

10-19-99



TOD M WOLF

**OCT 24 2003**

PATENTS & TRADEMARKS									
* -	DOCUMENT	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE			
A									
B									
C									
D									
E									
F									
G									
H									
I									
J									
K									

[illegible]

R	A. BRANCH. 1998 TIBS. Vol 23: 45-50.
S	
T	
U	

JAN 2 ZARA

10-19-95